BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19

• Press Releases

  NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor

  December 17, 2025

   · 

  3 min read
• Press Releases

  Beacon Therapeutics Treats First Patient in LANDSCAPE Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP)

  December 17, 2025

   · 

  4 min read
• Press Releases

  Elicio Therapeutics Reports Inducement Grants - December 16, 2025

  December 17, 2025

   · 

  2 min read
• Press Releases

  Annovis to Host Corporate Update Webinar on January 28, 2026

  December 17, 2025

   · 

  2 min read
• Press Releases

  Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

  December 17, 2025

   · 

  1 min read
• Press Releases

  Roche announces U.S. launch of next-generation cobas 6800/8800 systems and software, enhancing laboratory efficiency and testing capabilities

  December 17, 2025

   · 

  3 min read
• Press Releases

  Alnylam Announces Health Canada Approval of AMVUTTRA® (vutrisiran), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis

  December 17, 2025

   · 

  10 min read
• Press Releases

  Ambros Therapeutics Launches with $125 Million Series A Financing to Advance Neridronate Through Phase 3 Registrational Program for Complex Regional Pain Syndrome Type 1

  December 17, 2025

   · 

  6 min read
• Press Releases

  Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need

  December 17, 2025

   · 

  6 min read
• Press Releases

  PharmaLogic Announces Successful Supply of First Cohort Dosing for Ratio Therapeutics’ Phase 1/2 Study of a Novel FAP-Targeted Radiopharmaceutical in Late-Stage Aggressive Sarcomas

  December 17, 2025

   · 

  4 min read